Mn Services Vermogensbeheer B.V. Has $6.67 Million Holdings in ABIOMED, Inc. (ABMD)

Mn Services Vermogensbeheer B.V. grew its stake in ABIOMED, Inc. (NASDAQ:ABMD) by 1.7% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 23,368 shares of the medical equipment provider’s stock after buying an additional 400 shares during the period. Mn Services Vermogensbeheer B.V.’s holdings in ABIOMED were worth $6,674,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the business. State Treasurer State of Michigan lifted its position in shares of ABIOMED by 0.3% during the 1st quarter. State Treasurer State of Michigan now owns 33,000 shares of the medical equipment provider’s stock worth $9,424,000 after purchasing an additional 100 shares during the last quarter. Enlightenment Research LLC bought a new position in ABIOMED during the first quarter valued at about $400,000. Carillon Tower Advisers Inc. increased its stake in ABIOMED by 23.7% during the first quarter. Carillon Tower Advisers Inc. now owns 217,274 shares of the medical equipment provider’s stock valued at $62,050,000 after acquiring an additional 41,589 shares during the period. Stephens Investment Management Group LLC increased its stake in ABIOMED by 0.8% during the first quarter. Stephens Investment Management Group LLC now owns 158,649 shares of the medical equipment provider’s stock valued at $45,309,000 after acquiring an additional 1,294 shares during the period. Finally, Twin Capital Management Inc. bought a new position in ABIOMED during the first quarter valued at about $1,993,000. 87.85% of the stock is owned by institutional investors.

Several equities analysts recently issued reports on ABMD shares. Zacks Investment Research upgraded ABIOMED from a “hold” rating to a “buy” rating and set a $370.00 price target on the stock in a research note on Friday, January 18th. BTIG Research reiterated a “buy” rating and issued a $400.00 price objective on shares of ABIOMED in a research note on Tuesday, January 22nd. They noted that the move was a valuation call. BidaskClub lowered ABIOMED from a “buy” rating to a “hold” rating in a research note on Wednesday, January 30th. Finally, ValuEngine upgraded ABIOMED from a “hold” rating to a “buy” rating in a research note on Tuesday, February 12th. Three analysts have rated the stock with a sell rating and five have issued a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $408.67.

ABMD stock opened at $256.69 on Thursday. ABIOMED, Inc. has a 1-year low of $228.00 and a 1-year high of $459.75. The company has a market capitalization of $11.38 billion, a PE ratio of 71.30, a P/E/G ratio of 1.98 and a beta of 0.29.

ABIOMED (NASDAQ:ABMD) last released its quarterly earnings data on Thursday, May 2nd. The medical equipment provider reported $1.60 earnings per share for the quarter, beating the consensus estimate of $1.07 by $0.53. ABIOMED had a return on equity of 20.32% and a net margin of 33.66%. The company had revenue of $207.08 million for the quarter, compared to analyst estimates of $218.88 million. During the same period in the prior year, the company posted $0.80 EPS. The company’s revenue was up 18.7% compared to the same quarter last year. On average, sell-side analysts predict that ABIOMED, Inc. will post 4.56 earnings per share for the current year.

In other news, Director Martin P. Sutter sold 4,664 shares of the business’s stock in a transaction that occurred on Wednesday, May 8th. The stock was sold at an average price of $259.97, for a total value of $1,212,500.08. Following the transaction, the director now directly owns 192,550 shares of the company’s stock, valued at approximately $50,057,223.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Martin P. Sutter sold 20,000 shares of the business’s stock in a transaction that occurred on Friday, February 15th. The stock was sold at an average price of $360.16, for a total value of $7,203,200.00. Following the completion of the transaction, the director now directly owns 195,491 shares in the company, valued at $70,408,038.56. The disclosure for this sale can be found here. Corporate insiders own 3.50% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Mn Services Vermogensbeheer B.V. Has $6.67 Million Holdings in ABIOMED, Inc. (ABMD)” was originally reported by Markets Daily and is owned by of Markets Daily. If you are accessing this article on another publication, it was illegally copied and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://www.themarketsdaily.com/2019/05/16/mn-services-vermogensbeheer-b-v-has-6-67-million-holdings-in-abiomed-inc-abmd.html.

ABIOMED Profile

ABIOMED, Inc engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite.

Featured Article: Stop Order Uses For Individual Investors

Want to see what other hedge funds are holding ABMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ABIOMED, Inc. (NASDAQ:ABMD).

Institutional Ownership by Quarter for ABIOMED (NASDAQ:ABMD)

Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.